Wedbush Reaffirms “Buy” Rating for United Therapeutics (NASDAQ:UTHR)

Wedbush reiterated their buy rating on shares of United Therapeutics (NASDAQ:UTHR) in a research note released on Wednesday, BenzingaRatingsTable reports. The brokerage currently has a $244.00 target price on the biotechnology company’s stock, up from their prior target price of $243.00.

Several other research firms also recently weighed in on UTHR. HC Wainwright increased their price objective on United Therapeutics from $85.00 to $125.00 and gave the company a neutral rating in a report on Thursday, June 25th. TheStreet raised United Therapeutics from a c rating to a b rating in a report on Wednesday, April 29th. Cowen reissued a buy rating and issued a $145.00 price objective on shares of United Therapeutics in a report on Friday, June 12th. Zacks Investment Research raised United Therapeutics from a hold rating to a buy rating and set a $128.00 price objective for the company in a report on Sunday, May 3rd. Finally, ValuEngine downgraded United Therapeutics from a sell rating to a strong sell rating in a report on Thursday, July 2nd. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. United Therapeutics presently has an average rating of Hold and an average target price of $141.67.

Shares of UTHR opened at $111.47 on Wednesday. The stock has a 50 day moving average price of $117.48 and a 200 day moving average price of $106.45. The company has a quick ratio of 8.46, a current ratio of 7.43 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $5.00 billion, a price-to-earnings ratio of 11.65 and a beta of 0.86. United Therapeutics has a 52-week low of $75.58 and a 52-week high of $127.79.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $2.41 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $2.41. The firm had revenue of $362.00 million during the quarter, compared to the consensus estimate of $339.97 million. United Therapeutics had a return on equity of 14.90% and a net margin of 30.04%. The firm’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same period in the prior year, the company posted $3.63 earnings per share. On average, equities analysts anticipate that United Therapeutics will post 10.4 EPS for the current fiscal year.

In other United Therapeutics news, Director Tommy G. Thompson sold 3,100 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $112.56, for a total value of $348,936.00. Following the completion of the transaction, the director now owns 9,050 shares in the company, valued at $1,018,668. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Judy D. Olian sold 4,510 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $124.96, for a total value of $563,569.60. Following the completion of the transaction, the director now owns 3,490 shares of the company’s stock, valued at approximately $436,110.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 242,210 shares of company stock valued at $28,840,232. Corporate insiders own 10.90% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in UTHR. CWM LLC raised its position in United Therapeutics by 696.2% in the second quarter. CWM LLC now owns 207 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 181 shares in the last quarter. Altshuler Shaham Ltd purchased a new position in United Therapeutics in the first quarter worth $28,000. Signaturefd LLC increased its position in shares of United Therapeutics by 139.6% in the second quarter. Signaturefd LLC now owns 321 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 187 shares in the last quarter. Banque Cantonale Vaudoise purchased a new position in shares of United Therapeutics in the second quarter valued at $69,000. Finally, First Mercantile Trust Co. purchased a new position in shares of United Therapeutics in the first quarter valued at $72,000. Hedge funds and other institutional investors own 97.99% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Featured Story: Gap Up Stocks

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.